New Scope of the Document Although reports on cardiovascular screening efficacy have predominantly involved populations of adolescents and young adults participating in competitive athletics, the ...context of the present discussion is intentionally (and necessarily) much more expansive. ...it is underscored that the present report is not limited in scope to universal mass screening for athlete populations but importantly includes considerations for screening large, young, and truly general populations (school-aged, 12-25 years old, of both sexes) with respect to relevant logistical, ethical, legal, and societal issues (e.g., in the United States or other countries or communities of various sizes, in schools, or in regional or military populations).
Full text
Available for:
GEOZS, IJS, IMTLJ, KILJ, KISLJ, NLZOH, NUK, OILJ, PNG, SAZU, SBCE, SBJE, UILJ, UL, UM, UPCLJ, UPUK, ZAGLJ, ZRSKP
Patients with hypertrophic cardiomyopathy have clinical, logistical, and emotional needs that had previously lacked attention and a coordinated approach. The United States-based HCMA recognized ...Center of Excellence model coupled with strong patient education, support and advocacy services can serve as a model for other nations. Patients benefit from peer support and high-volume HCM care.
Full text
Available for:
NUK, OILJ, SAZU, UKNU, UL, UM, UPUK
The results of this study are more disturbing than the concept alone, reporting 2 deaths and 7 serious complications, including ventricular fibrillation, need for permanent pacing, valve replacement, ...implantable cardioverter-defibrillator implantation, failure and need for second attempt, burns, and myectomy--totalling a complication rate of more than 20%.
Full text
Available for:
GEOZS, IJS, IMTLJ, KILJ, KISLJ, NLZOH, NUK, OILJ, PNG, SAZU, SBCE, SBJE, UILJ, UL, UM, UPCLJ, UPUK, ZAGLJ, ZRSKP
Abstract only Introduction: Hypertrophic cardiomyopathy (HCM) is a common heart condition that affects at least 1:500 individuals in the United States. Patients with HCM can suffer from ...life-threatening arrhythmias, requiring implantable cardiac devices and several limitations in daily life activities. Only limited data exist describing impacts on quality of life among these patients. Hypothesis: We hypothesize that patients living with HCM may suffer from an increased prevalence of depressive or anxiety related symptoms. Methods: Patients were approached via survey invitation on the Hypertrophic Cardiomyopathy Association (HCMA) website. Surveys were made accessible to all the members of the HCMA who had provided an active email address. Survey data were collected via the HCMA and de-identified for subsequent analyses. Demographic variables along with 40 questions assessing signs and symptoms of depression and anxiety were included. Answers to questions ranged from never to nearly always and were transformed on a Likert scale. Results: Survey invitations were sent to 1425 patients/families with HCM. Of these, 737 (52%) completed the survey adequately. Around 93% of respondents were Caucasian, with a mean age of 52.1 ±1.4, and composed of almost an equal number of men and women. Around 70% of patients with HCM reported that they never or rarely felt worthless, helpless, hopeless, anxious or depressed. Meanwhile, less than 3% reported depressive or anxiety related symptoms on a daily basis. On the contrary, around 52% of respondents found it difficult to engage in daily exercise or activities such as lifting items and helping with household chores. Conclusions: In conclusion, patients with HCM infrequently suffered from depressive or anxiety related symptoms, while many reported increased levels of exercise-related limitations. Further studies are warranted to better understand the effects of HCM on the physical and psychological well-being.
Written by the authority on hypertrophic cardiomyopathy (HCM) and an HCM patient, and fully endorsed by the Hypertrophic Cardiomyopathy Association (HCMA), the leading advocacy and support ...organization, the 3rd Edition of this best-selling guide offers unparalleled insight into all aspects of living with and treating HCM. Accessible and practical, A Guide to Hypertrophic Cardiomyopathy For Patients, Their Families and Interested Physicians 3rd Edition: Answers the most pressing questions posed by patients, their families, and non-specialistshealth professionals involved in their care Covers everything from what is HCM and initial diagnosis of this increasingly prevalentcondition to the latest treatment options Reflects the first-ever HCM guidelines published by the American Heart Association in 2011
PDF
